In a meta-analysis, overall, 1.24% of PD-L1 inhibitor-associated fatal side effects occurred; this was significantly greater in non-squamous NSCLC, phase I trial, and among the group of middle-aged people while comparing to the equivalent reference group. The gene discussed is CD274; the disease is non-small cell lung carcinoma.